Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

10.0K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
10.0K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

5.2K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
5.2K
Spare Receptors01:30

Spare Receptors

4.7K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
4.7K
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

5.0K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
5.0K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

4.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.0K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

838
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
838

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive Evaluation of Indazole-Based Synthetic Cannabinoid Receptor Agonists with Aliphatic Tail Groups: In Vitro Activities, Metabolic Stability, and In Vivo Pharmacokinetics.

ACS chemical neuroscience·2026
Same author

PN6047 Demonstrates Broad Preclinical Efficacy in Headache Models as a Novel Delta-Opioid Receptor Agonist.

bioRxiv : the preprint server for biology·2026
Same author

International Union of Basic and Clinical Pharmacology. CXXII. Applying an objective evaluation to the status of class A orphan G protein-coupled receptors.

Pharmacological reviews·2026
Same author

AB-MDMSBA-Not a Synthetic Cannabinoid Receptor Agonist.

Pharmacology research & perspectives·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025
Same author

Insights into cannabinoid receptor 2 (CB2) anterograde trafficking and pharmacological chaperoning.

Cellular and molecular life sciences : CMLS·2025
Same journal

Preface.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides: From permeability assay toolbox to data-driven discovery.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides derived from phage display.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Physiological strategies for brain delivery.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides derived from natural proteins.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

In vitro blood-brain barrier models for the study of brain shuttle peptide transport.

Advances in pharmacology (San Diego, Calif.)·2026
See all related articles

Related Experiment Video

Updated: Feb 24, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.3K

Functional Selectivity at Cannabinoid Receptors.

Richard Priestley1, Michelle Glass2, David Kendall3

  • 1Alzheimer's Research UK Drug Discovery Institute, University of Oxford, Oxford, United Kingdom.

Advances in Pharmacology (San Diego, Calif.)
|August 23, 2017
PubMed
Summary
This summary is machine-generated.

Functional selectivity allows agonists to trigger specific G protein-coupled receptor signaling pathways based on their structure. Understanding this biased agonism is crucial for developing targeted cannabinoid receptor drugs with desired effects and fewer side effects.

Keywords:
Agonist biasAgonist-directed traffickingDifferential signalingFunctional selectivity

More Related Videos

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
14:25

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans

Published on: September 21, 2019

7.7K
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

585

Related Experiment Videos

Last Updated: Feb 24, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.3K
Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
14:25

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans

Published on: September 21, 2019

7.7K
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

585

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Biochemistry

Background:

  • G protein-coupled receptor (GPCR) signaling traditionally assumes a single pathway activation.
  • Agonists can induce distinct conformational changes in receptors, leading to varied downstream signaling.
  • Functional selectivity, or biased agonism, describes this phenomenon of ligand-directed signaling.

Purpose of the Study:

  • To highlight the importance of functional selectivity in GPCR signaling.
  • To illustrate how structural differences in agonists lead to differential pathway activation.
  • To emphasize the need for evaluating functional selectivity in drug development, particularly for cannabinoid receptors.

Main Methods:

  • Review of existing literature on GPCR signaling and functional selectivity.
  • Analysis of signaling profiles of various cannabinoid receptor agonists (e.g., HU-210, anandamide, WIN 55,212).
  • Examination of differential activation of G proteins (Gi/o, Gs, Gq/11) and β-arrestin pathways.
  • Reference to a study characterizing CB2 agonist pharmacology (Soethoudt et al., 2017).

Main Results:

  • Agonists can activate or inhibit specific downstream pathways based on receptor conformation.
  • Cannabinoid receptor agonists exhibit biased signaling through different G protein subtypes and β-arrestins.
  • Structural variations in agonists result in significant differences in signaling outcomes and potential side effects.
  • CB2 agonists show marked bias in activating pathways like cAMP accumulation, ERK phosphorylation, and β-arrestin recruitment.

Conclusions:

  • Functional selectivity is a critical determinant of agonist efficacy and safety.
  • Understanding biased agonism is essential for designing selective drugs targeting specific signaling pathways.
  • Comprehensive evaluation of functional selectivity is necessary for successful agonist drug development, especially for cannabinoid receptor modulators.